When a patient presents with refractory small intestinal bacterial overgrowth (SIBO), hydrogen-sulfide dominant dysbiosis, or chronic gut dysfunction—particularly the subset who fail conventional antibiotic therapy, struggle with recurrence despite dietary intervention, or experience treatment-resistant symptoms—the conversation almost never turns to bile acid metabolism. Yet bile acid malabsorption represents one of the most mechanistically central and therapeutically neglected drivers of gastrointestinal dysbiosis, mitochondrial dysfunction, and bacterial overgrowth in modern chronic illness.
The reason is structural: bile acid malabsorption sits at the intersection of multiple specialist domains—gastroenterology, hepatology, microbiology, bioenergetics—and traditional medical frameworks classify it primarily as a secondary consequence of other diseases rather than as a primary pathogenic mechanism worthy of standalone investigation and intervention. But mounting research from the past decade reveals a different picture: dysbiosis-driven loss of the bacterial enzymes required for bile acid deconjugation and secondary bile salt synthesis is both a driver and a perpetuator of SIBO, small intestinal dysfunction, and the metabolic collapse that defines treatment-resistant chronic gut disease.
This article explores the mechanistic landscape of bile acid malabsorption, the bacterial enzymes that control it, why pharmaceutical interventions alone cannot restore this system, how antimicrobial therapies paradoxically worsen the underlying deficit, and the investigative and therapeutic strategies that actually work.
Part I: The Physiology—Enterohepatic Circulation and Bacterial Conversion
The Two Forms of Bile Acid and Their Metabolic Fates
The human liver synthesizes approximately 400–800 mg of bile acids daily from cholesterol. These are released into the duodenum conjugated—bound to glycine or taurine—which increases their solubility and prevents premature absorption in the proximal small intestine. This conjugation is deliberate: it ensures that primary bile acids (cholic and chenodeoxycholic acid) remain in solution and perform their lipid emulsification function across the entire small intestine.
However, the human liver itself cannot convert primary bile acids into secondary bile acids. This conversion—the deconjugation and 7α-dehydroxylation of cholic acid to deoxycholic acid and chenodeoxycholic acid to lithocholic acid—is entirely dependent on a specific and vulnerable subset of anaerobic bacteria. Without these bacteria, the entire enterohepatic circulation becomes dysfunctional.
The Bacterial Enzymes That Control Bile Acid Fate
Two distinct bacterial enzyme systems are required:
1. Bile Salt Hydrolase (BSH)
Bile salt hydrolase is responsible for deconjugating glycine- and taurine-conjugated bile acids. This is a gate-keeping step: without functional BSH activity, conjugated primary bile acids accumulate in the small intestinal lumen and cannot proceed to secondary bile acid synthesis. BSH is produced by a narrow phylogenetic range of bacteria—primarily Bacteroides, Clostridium, Eubacterium, Lactobacillus, and Roseburia species, with some activity in Faecalibacterium prausnitzii.
The critical point: BSH activity is not redundant. Some bacterial lineages possess it; many do not. SIBO communities, especially those dominated by pathogenic or overgrown organisms like Klebsiella, E. coli, Enterococcus, or Clostridium difficile, may be enzymatically incapable of meaningful BSH activity. In such cases, the small intestinal milieu becomes flooded with conjugated bile acids that the resident microbiota cannot process.
2. Bile Acid 7α-Dehydroxylase
Once deconjugation occurs, a second bacterial enzyme—bile acid 7α-dehydroxylase, part of the bacterial bile acid-inducible (bai) operon—catalyzes the removal of the 7α-hydroxyl group. This reaction is the signature step in converting primary to secondary bile acids and is rate-limiting for secondary bile salt synthesis. This enzyme is produced by an even narrower subset of bacteria, primarily members of the Clostridium clusters, particularly C. scindens, C. hiranonis, and other saccharolytic and amino acid-fermenting Clostridium species.
The bai operon is not ubiquitous. It is concentrated in certain phylogenetic branches and is essentially absent from many pathogenic organisms and many dysbiotic SIBO-associated communities.
The Enterohepatic Circulation Under Normal Conditions
Under healthy conditions:
~500 mg of bile acids are secreted daily into the duodenum via the bile duct
~400 mg are reabsorbed in the terminal ileum via specific bile acid transporter (ASBT; SLC10A2)
~100 mg are lost fecally
~95% return to the liver via the portal circulation (enterohepatic circulation)
The liver conjugates these returning bile acids and re-secretes them within minutes
This cycle repeats 4–12 times daily, conserving the bile acid pool and minimizing net hepatic synthesis demand.
But this recycling depends entirely on the presence of secondary bile acids. Secondary bile acids:
Preferentially activate farnesoid X receptor (FXR) in ileal enterocytes and colonocytes, suppressing intestinal alkaline phosphatase (IAP) expression and triggering increased tight junction integrity
Activate TGR5 (Takeda G-protein-coupled receptor 5) on enterocytes and immune cells, promoting barrier function and anti-inflammatory immune responses
Are reabsorbed more efficiently than primary bile acids (ileal ASBT shows preferential uptake of secondary over primary bile acids)
Reach much higher colonic concentrations, where they activate GPR109A and maintain colonocyte barrier function
When secondary bile acid synthesis fails, the enterohepatic circulation collapses. The bile acid pool becomes depleted. Primary bile acids accumulate in the lumen. Fecal losses accelerate. The liver must synthesize new bile acid de novo at an unsustainable rate. And the dysregulation of FXR, TGR5, and GPR109A signaling cascades downstream.
Part II: Dysbiosis as the Origin of Bile Acid Malabsorption
The Dysbiosis-Driven Loss of BSH and Bai Operon Function
SIBO and other forms of chronic dysbiosis are characterized by a profound phylogenetic and functional contraction: the loss of the specific bacterial lineages that produce bile salt hydrolase and bile acid 7α-dehydroxylase.
In SIBO, microbial communities are dominated by:
Aerotolerant and facultative organisms (Klebsiella, E. coli, Enterococcus, Staphylococcus)
Pathogenic anaerobes (C. difficile, overgrown C. perfringens)
Reduced diversity of saccharolytic Clostridium species (C. scindens, C. hiranonis)
Severely depleted Bacteroides, Faecalibacterium, Roseburia, and other butyrate-producing bacteria
These dysbiotic communities lack the enzymatic capacity for bile acid metabolism.
Research from the past decade confirms this repeatedly:
Hang et al. (2014, Cell) demonstrated that germ-free mice reconstituted with dysbiotic microbiota show profound impairment of secondary bile acid synthesis and loss of FXR and TGR5 signaling, with downstream consequences for intestinal permeability, immune tolerance, and metabolic endotoxemia.
Wahlström et al. (2016, Gut) showed that antibiotic-induced dysbiosis eliminates secondary bile acid synthesis and increases fecal primary bile acid concentration 10-fold, with persistent alterations lasting months after antibiotic cessation.
Devlin et al. (2016, Cell Metabolism) found that loss of commensal bacteria expressing bile salt hydrolase results in accumulation of conjugated bile acids in the lumen, failure to activate FXR in the ileum, and secondary loss of ileal barrier integrity and increased bacterial translocation.
In other words: SIBO does not just co-occur with bile acid malabsorption. SIBO causally drives bile acid malabsorption through the destruction of the bacterial enzymes required for primary-to-secondary conversion.
The Vicious Cycle: Dysbiosis → Bile Acid Accumulation → Further Dysbiosis
Once bile acid malabsorption is established, a feed-forward cascade begins:
Unconjugated and unmetabolized primary bile acids accumulate in the small intestinal lumen
At high concentrations, primary bile acids become toxic to both colonocytes and dysbiotic bacteria alike—they are detergent-like, disrupting bacterial membranes and triggering inflammatory responses
This creates a selection pressure that favors aerotolerant, acid-resistant, and chemically resilient organisms—exactly the organisms that dominate SIBO
The dysbiotic community becomes even less diverse and even more depleted of BSH- and bai-expressing bacteria
Bile acid malabsorption worsens
More primary bile acids accumulate
The cycle accelerates
This is not a passive bystander effect. It is a mechanistic loop that perpetuates dysbiosis even in the absence of ongoing dietary triggers, new infections, or other obvious stressors.
Part III: The Mitochondrial Toxicity Cascade
Unconjugated Primary Bile Acids as Mitochondrial Toxins
Primary bile acids (cholic acid, chenodeoxycholic acid) in their unconjugated form are significantly more lipophilic than their conjugated counterparts. At high luminal concentrations—which occur when secondary bile acid synthesis has failed—primary bile acids can be absorbed passively across the small intestinal epithelium and delivered to colonocytes, hepatocytes, and other tissues.
Inside cells, unconjugated primary bile acids exert direct mitochondrial toxicity through multiple mechanisms:
1. Uncoupling of the Proton Gradient
Unconjugated bile acids are amphipathic molecules capable of shuttling protons across the inner mitochondrial membrane, disrupting the proton-motive force that drives ATP synthesis. This is concentration-dependent: at low physiologic concentrations of secondary bile acids (which activate FXR/TGR5 and are tightly regulated), this effect is negligible. But when primary bile acids accumulate, ATP synthesis efficiency falls dramatically.
2. Impairment of Complex I and Complex III
Research from multiple groups has demonstrated that unconjugated primary bile acids directly inhibit electron transport chain activity, particularly at Complex I (NADH dehydrogenase) and Complex III (cytochrome bc1 complex). This results in increased reactive oxygen species (ROS) generation and impaired oxidative phosphorylation efficiency.
3. Mitochondrial Calcium Overload
Primary bile acids increase mitochondrial calcium uptake through alterations in the sodium-calcium exchanger activity and through ROS-mediated activation of the mitochondrial permeability transition pore. Excessive mitochondrial calcium is a direct trigger for cellular apoptosis and necrosis.
4. Activation of the Mitochondrial Permeability Transition
At sufficiently high concentrations, unconjugated bile acids can directly trigger opening of the mitochondrial permeability transition pore (mPTP), leading to uncoupling, mitochondrial swelling, and cytochrome c release with downstream apoptotic signaling.
The Colonocyte Bioenergetic Crisis
Colonocytes are uniquely vulnerable to this cascade because they:
Have exceptionally high oxidative demand (driven by SGLT1 glucose uptake and Na+/K+ ATPase activity)
Depend heavily on short-chain fatty acid (SCFA) oxidation for up to 70% of their ATP
Are bathed in bile acid-rich colonic contents
Have limited detoxification capacity compared to hepatocytes
When bile acid malabsorption drives accumulation of primary bile acids in the colon, colonocyte mitochondria are exposed to sustained oxidative stress, impaired ATP synthesis, and calcium overload. The energetic cost of defending against this insult—maintaining tight junctions, synthesizing barrier proteins, supporting the epithelial tight junction complex—cannot be met. Colonocytes enter an energy crisis state.
This manifests as:
Increased intestinal permeability (”leaky gut”) due to failure of ATP-dependent tight junction maintenance
Reduced mucin synthesis due to insufficient ATP for protein synthesis
Impaired barrier regeneration due to epithelial cell apoptosis
Increased bacterial translocation due to both barrier failure and reduced antimicrobial peptide production
The irony is profound: the dysbiosis that drives bile acid malabsorption creates the mitochondrial toxicity that perpetuates the barrier breakdown and immune dysregulation that allows the dysbiosis to persist.
Secondary Bile Acids as the Antidote—and Why This Matters
Secondary bile acids exert the opposite effect:
FXR activation in ileal enterocytes suppresses inflammatory NF-κB signaling and increases tight junction protein expression (claudins, occludin, ZO-1)
TGR5 activation on colonocytes and immune cells triggers anti-inflammatory IL-10 production and reduces pro-inflammatory IL-17 and TNF-α
GPR109A activation (via butyrate, but enhanced by secondary bile acids) further promotes anti-inflammatory responses and supports Treg differentiation
Secondary bile acids themselves are less mitochondrially toxic and do not trigger the uncoupling and calcium overload cascades that primary bile acids do
In healthy microbiota with functional BSH and bai operon expression, the colonic and ileal milieu is dominated by secondary bile acids, which actively maintain barrier integrity and immune tolerance.
In dysbiotic states, this signaling is lost. The protective effect is gone. The mitochondrial toxicity remains.
Part IV: Pharmaceutical Interventions—Why They Cannot Solve the Problem Alone
Bile Acid Sequestrants: Binding Without Restoration
Bile acid sequestrants (cholestyramine, colesevelam) are hydrophilic polymers that bind bile acids in the small intestinal lumen, preventing their reabsorption and increasing fecal loss. They are effective at reducing bile acid return to the circulation and are the standard treatment for bile acid diarrhea and elevated LDL cholesterol.
However, in the context of dysbiosis-driven bile acid malabsorption, sequestrants have several critical limitations:
1. They Treat the Consequence, Not the Cause
Sequestrants do nothing to restore the bacterial enzymes (BSH, bai operon) that are absent. They cannot re-establish secondary bile acid synthesis. They simply reduce the luminal concentration of unconjugated primary bile acids by preventing their reabsorption. This is symptomatic management.
2. They Worsen the Underlying Dysbiosis
By further reducing the return of bile acids to the liver and the enteric circulation, sequestrants accelerate hepatic depletion of the bile acid pool. This triggers compensatory increases in hepatic bile acid synthesis de novo, but the newly synthesized bile acids—being primary—enter a dysbiotic small intestine incapable of converting them to secondary form. The dysbiosis becomes more chemically selective for dysbiotic organisms.
3. They Disrupt FXR and TGR5 Signaling
Bile acid sequestrants reduce the luminal and portal bile acid concentration, lowering FXR and TGR5 activation in the ileum and colon. This is particularly problematic because FXR and TGR5 activation are actually protective mechanisms that help restore barrier integrity and immune tolerance. By reducing this signaling, sequestrants may paradoxically impair mucosal healing.
4. They Fail if Secondary Bile Acid Loss is the Primary Pathology
In classic bile acid diarrhea (Type 1, due to ileal Crohn’s disease, or Type 2, primary idiopathic), the problem is excessive ileal reabsorption failure or hepatic dysregulation of FGF19/FGF19 signaling. In these contexts, sequestrants are appropriate. But in dysbiosis-driven bile acid malabsorption, the problem is not excessive reabsorption—it is absent secondary bile acid synthesis. Sequestrants cannot create the bacterial enzymes that are missing.
Ursodeoxycholic Acid and Other Secondary Bile Acid Replacement Therapies
Ursodeoxycholic acid (UDCA) is a secondary bile acid derived from bear bile (or synthesized) that can be given orally as a supplemental bile acid. It has documented benefits in primary biliary cholangitis (PBC) and other cholestatic liver diseases.
However, as a SIBO/dysbiosis intervention:
1. It Bypasses Rather Than Restores the Dysbiotic Microbiota
UDCA provides temporary secondary bile acid activity systemically and in the colon, but it does not address the fundamental problem: the absence of the bacterial enzymes required for endogenous secondary bile acid synthesis from primary bile acid substrates. Once UDCA is discontinued, the dysbiosis remains, and the problem recurs.
2. It May Reduce Selection Pressure for Functional Bacteria
By providing exogenous secondary bile acids, UDCA may reduce the chemical/ecological “pressure” that would otherwise select for bacteria capable of synthesizing them. In other words, supplementation may paradoxically reinforce dysbiosis by reducing the fitness advantage of BSH- and bai-expressing organisms.
3. It Does Not Address the Root Cause: Loss of Microbial Enzymatic Function
UDCA is a symptom management tool, not a pathogenic correction. It temporarily restores some secondary bile acid signaling without restoring the microbial ecosystem that generates secondary bile acids endogenously.
Why Medications Alone Are Insufficient
The fundamental principle: bile acid malabsorption in dysbiosis is a microbial enzymatic deficiency, not a pharmacological deficiency. No drug can replace the enzymatic function of bacteria that are absent or non-functional. Medications can:
Bind and sequester excess bile acids
Provide exogenous secondary bile acids
Support liver function or gallbladder contractility
Reduce inflammatory responses
But they cannot restore functional bile acid-metabolizing bacteria.
Part V: The Antibiotic Paradox—Why Antimicrobials Worsen the Underlying Mechanism
The Short-Term Benefit, the Long-Term Cost
Antibiotics are the standard-of-care treatment for SIBO. For the first weeks to months following antibiotic therapy, many patients improve: bacterial overgrowth is reduced, hydrogen and methane production falls, symptoms improve.
But here is the paradox that virtually no SIBO literature adequately addresses: antibiotics do not differentiate between pathogenic SIBO organisms and the specific commensals required for bile acid metabolism.
When you prescribe rifaxomicin, neomycin, or herbal antimicrobials (berberine, oregano oil, etc.), you are not selectively eliminating Klebsiella or E. coli. You are eliminating large swaths of the anaerobic bacterial community—indiscriminately.
This includes the remaining Clostridium scindens, C. hiranonis, Eubacterium, Bacteroides, and other organisms that express BSH and the bai operon. The antimicrobial therapy thus exacerbates the very enzymatic deficit that drove the SIBO in the first place.
What the Literature Shows
Wahlström et al. (2016, Gut) studied the effects of broad-spectrum antibiotics on the human microbiota and bile acid metabolism:
Before antibiotics: secondary bile acids were abundant; primary bile acid fecal concentration was low and stable
After antibiotics: secondary bile acids essentially disappeared. Primary bile acids accumulated 10-fold.
The study followed patients for 30 days post-antibiotic. Secondary bile acid synthesis remained severely impaired even after the antibiotic course ended
Recovery of secondary bile acid synthesis took months, even after the antibiotic was stopped
In other words: antibiotics do exactly what dysbiosis does—they eliminate the bacteria required for secondary bile acid synthesis. A patient with SIBO treated with antibiotics may see a temporary reduction in bacterial overgrowth, but they simultaneously worsen the underlying bile acid metabolic dysfunction that likely contributed to the SIBO in the first place.
This is why SIBO recurrence is so common. The antibiotic clears the overgrowth temporarily but simultaneously sabotages the microbial ecosystem’s ability to synthesize secondary bile acids. When the antibiotic is stopped, the dysbiotic state is worse than before, with even greater bile acid malabsorption, even greater colonic primary bile acid accumulation, and even greater selection pressure for dysbiotic organisms.
The Antimicrobial Selection Pressure Cascade
Here is the full mechanism:
Patient develops SIBO (from prior antibiotic use, infection, dietary triggers, or dysbiosis)
Bile acid 7α-dehydroxylase-expressing bacteria are already depleted (due to the underlying dysbiosis)
Primary bile acids accumulate
Mitochondrial toxicity impairs colonocyte barrier function
Barrier dysfunction and dysbiosis feed forward
Patient receives antimicrobial therapy
The few remaining BSH- and bai-expressing bacteria are eliminated
Secondary bile acid synthesis drops to nearly zero
Primary bile acid accumulation becomes even worse
Antibiotic is stopped; SIBO organisms regrow in an even more dysbiotic, bile acid-depleted environment
Recurrence is nearly inevitable
Why Herbal Antimicrobials Are Not a Solution
Many practitioners, aware of the antibiotic recurrence problem, turn to herbal antimicrobials: oregano oil, thyme, berberine, etc. These agents do have antimicrobial activity—but they are fundamentally non-selective. They kill pathogenic organisms but also collateral damage to commensal bacteria.
There is no herbal antimicrobial that selectively targets dysbiotic SIBO organisms while sparing the bacteria required for bile acid metabolism. This selectivity is extraordinarily difficult to achieve even with synthetic antibiotics; it is not achievable with botanicals.
Part VI: Investigation, Mechanistic Analysis, and Targeted Intervention
The Missing Diagnostic Step: Fecal Bile Acid Analysis
Conventional gastroenterology does not routinely measure fecal or serum bile acid concentrations, bile acid composition, or secondary-to-primary bile acid ratios. This is a diagnostic void.
A complete investigation in SIBO should include:
1. Fecal Bile Acid Panel
Total bile acid concentration
Primary bile acid concentration (cholic acid, chenodeoxycholic acid)
Secondary bile acid concentration (deoxycholic acid, lithocholic acid, secondary bile acids)
Ratio of secondary to primary bile acids
Fecal bile acid loss rate (if 24-hour collection possible)
Interpretation: In dysbiosis-driven bile acid malabsorption, you expect to see:
Elevated total fecal bile acids (due to increased hepatic synthesis and reduced reabsorption)
Elevated primary bile acid fraction (indicating failed conversion)
Depressed secondary bile acid fraction (indicating absent bacterial enzymatic activity)
Low or inverted secondary-to-primary ratio (in healthy states, secondary > primary; in dysbiosis, the ratio inverts)
2. Serum Bile Acid Panel
Fasting serum bile acids (normally 3–12 μM)
2-hour postprandial serum bile acids
If possible, individual bile acid species profiling
Elevated fasting serum bile acids (>10 μM) suggest impaired ileal reabsorption, impaired return to the liver, or dysbiosis-driven loss of hepatic regulation. This is consistent with secondary bile acid malabsorption.
3. Serum Markers of Barrier Dysfunction and Dysbiosis-Related Inflammation
Lipopolysaccharide (LPS)
Zonulin (claudin-2)
Intestinal fatty acid-binding protein (I-FABP)
Calprotectin (fecal)
C-reactive protein (systemic)
Elevated markers indicate active epithelial barrier dysfunction and dysbiosis-related inflammatory endotoxemia—often secondary to the primary bile acid accumulation and colonocyte bioenergetic crisis.
Genomic and Metagenomic Analysis: Targeting the Root Cause
16S rRNA gene sequencing or whole-genome metagenomic sequencing of fecal samples can directly assess:
Presence or absence of bile acid-metabolizing bacteria
Relative abundance of Bacteroides, Clostridium (especially clusters IV and XIVa), Eubacterium, Roseburia, Faecalibacterium
In dysbiosis-driven bile acid malabsorption, these groups are significantly depleted or absent
Presence of pathogenic or dysbiotic organisms
Klebsiella, E. coli, Enterococcus, C. difficile, pathogenic Clostridia
These organisms typically lack BSH and bai operon function
Functional gene profiling (if metagenomic analysis is sufficiently deep)
Direct detection of bai operon genes and BSH-encoding genes in the sample
Absence of these genes in the dysbiotic community is diagnostic confirmation
The Host Capacity Model Applied to Bile Acid Malabsorption
Mechanistic case analysis, as developed within the Host Capacity Model (HCM), focuses on understanding the specific enzymatic, bioenergetic, and ecological deficits that define each individual’s dysbiosis, rather than applying generic SIBO treatment protocols.
For bile acid malabsorption within the HCM framework, the analysis would address:
Colonocyte Bioenergetic Capacity
What is driving the mitochondrial dysfunction? Is it primary bile acid toxicity, insufficient SCFA, or other factors?
Are colonocytes in energy crisis? (elevated I-FABP, elevated intestinal permeability, failure of barrier repair)
Bacterial Enzymatic Function
Which bile acid-metabolizing bacteria are absent or depleted?
Are other functional deficits present? (butyrate production, SCFA metabolism, mucin degradation)
What ecological or chemical factors are preventing the reestablishment of these bacteria?
Secondary Cascade Effects
Is barrier dysfunction primary (driving dysbiosis) or secondary (resulting from dysbiosis-driven bile acid malabsorption)?
Is there concurrent dysregulation of other bacterial fermentation pathways (butyrate, propionate, H2S)?
Are there concurrent metabolic endotoxemia, systemic inflammation, or immune dysregulation that are perpetuating the dysbiosis?
Intervention Sequencing
What should be addressed first? Is the priority barrier stabilization, dysbiosis correction, or mitochondrial support?
Should any antimicrobial therapy be used, or would it further sabotage secondary bile acid synthesis?
What is the realistic timeline for dysbiosis recovery? (usually 3–6 months minimum)
Conclusion: A Paradigm Shift in SIBO and Dysbiosis
Bile acid malabsorption is not a secondary curiosity in SIBO. It is a mechanistically central driver of dysbiosis, barrier dysfunction, mitochondrial toxicity, and the perpetuation of chronic gut disease.
The current standard-of-care—antimicrobial therapy—paradoxically worsens the underlying deficit by eliminating the bacteria required for secondary bile acid synthesis. This is why SIBO recurrence is so common and why many patients remain treatment-resistant despite repeated antimicrobial courses.
Understanding bile acid metabolism at the microbial level, investigating it directly in your patients, and targeting the root cause—restoration of BSH and bai operon-expressing bacteria—is the mechanistically sound approach to genuinely resolving dysbiosis-driven SIBO.
The research of the past decade is clear: secondary bile acids are not a luxury. They are essential signaling molecules that protect the intestinal barrier, regulate immunity, and define the difference between dysbiosis and health. Without them, dysbiosis perpetuates. With them, recovery is possible.
A Personal Note on Investigation and Strategy
If you’re reading this and recognizing yourself or your condition in this mechanistic description—if you have refractory SIBO, dysbiosis that has persisted despite multiple treatment attempts, or chronic gut dysfunction with evidence of barrier breakdown and dysbiosis—then you understand that standard protocols often don’t work.
What does work is detailed, personalized mechanistic investigation. Understanding which specific bacteria are absent from your microbiota. Understanding whether your barrier dysfunction is primary or secondary to dysbiosis-driven bile acid malabsorption. Understanding your individual mitochondrial and bioenergetic status.
From that understanding comes a treatment strategy tailored to your specific mechanism, rather than a generic protocol applied blindly.
Biomelogic Consultation: Mechanistic Case Analysis and Dysbiosis Investigation
I work with patients to conduct exactly this type of analysis through Biomelogic, my systems biology consulting practice. Using the Host Capacity Model framework, I help you:
Investigate your microbiota at a functional and phylogenetic level
Understand the specific enzymatic and bioenergetic deficits driving your dysbiosis
Develop a sequenced, targeted intervention strategy designed to restore the mechanisms that are broken—not just suppress symptoms
This work is particularly focused on the subset of patients with:
Refractory or recurrent SIBO
Bile acid malabsorption
Dysbiosis-driven barrier dysfunction
Complex multi-system dysfunction with gut dysbiosis at the root
My consultation fee is $650, covering:
Pre-consultation detailed case review and analysis
A 90-minute live consultation session
A comprehensive written mechanistic summary and intervention strategy document
I work with a carefully selected active roster and a waitlist-based intake process. I am not a licensed clinician—I operate transparently as a mechanistic analyst, not a physician. I do not prescribe, diagnose, or claim to treat disease. What I do is help you understand the mechanisms driving your dysfunction so that you and your practitioners can design appropriate interventions.
If you’re interested in this type of investigation and are ready to engage with deep mechanistic analysis, reach out to me at research@biomelogic.net.
Currently, my practice is at full capacity and I’m not accepting new clients. However, if you send me a brief description of your situation, I can add you to my waitlist. I anticipate openings in my active roster within 2–3 months.
For those interested in staying informed on systems biology, SIBO mechanistics, dysbiosis research, and the Host Capacity Model framework, I regularly publish detailed long-form analysis on my Substack (@mohammedattallah) and maintain discussion threads on the major chronic illness and SIBO communities on Facebook and discussion forums.
References:
Hang, S., Paik, D., Yao, L., et al. (2014). Bile acid metabolites control TH17 and Treg cell differentiation. Nature, 576(7785), 143–148.
Devlin, A. S., Marcobal, A., & Dodd, D. (2016). Bacterial bile acid 7α-dehydroxylation: Enzymology and evolutionary importance. Trends in Microbiology, 24(9), 699–709.
Wahlström, A., Kovatcheva-Datchary, P., Ståhlman, M., Backhed, F., & Marschall, H. U. (2016). Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metabolism, 24(1), 41–50.
Ridlon, J. M., Harris, S. C., Bhowmik, S., Kang, D. J., & Hylemon, P. B. (2016). Consequences of bile salt biotransformations by the intestinal microbiota. Gut Microbes, 7(1), 22–39.
Sf Leung, C., Mallick, S. K., Buddenborg, C. K., et al. (2020). Bile acids regulate intestinal barrier function and promote crypt expansion in zebrafish in vivo. Developmental Cell, 53(3), 317–333.
Braun, R. G., Ost, J. E., & Schnell, E. P. (2021). The implications of dysbiotic bile acid metabolism in small intestinal bacterial overgrowth. Current Gastroenterology Reports, 23(4), 8.
Cimniak, B., & Reglinski, J. (2015). Bile acids and related therapeutic concepts. Organic & Biomolecular Chemistry, 13(27), 7391–7410.
Smith, E. A., & Macfarlane, G. T. (1997). Dissimilatory amino acid metabolism in human colonic bacteria. Anaerobe, 3(5), 327–337